Vigil Jacob M, Stith Sarah S, Reeve Anthony P
Department of Psychology, University of New Mexico, Albuquerque, NM, USA.
Department of Economics, University of New Mexico, Albuquerque, NM, USA.
Pain Res Manag. 2018 Jan 28;2018:5704128. doi: 10.1155/2018/5704128. eCollection 2018.
The decision to authorize a patient for continued enrollment in a state-sanctioned medical cannabis program is difficult in part due to the uncertainty in the accuracy of patient symptom reporting and health functioning including any possible effects on other medication use. We conducted a pragmatic convenience study comparing patient reporting of previous and current prescription opioid usage to the opioid prescription records in the Prescription Monitoring Program (PMP) among 131 chronic pain patients (mean age = 54; 54% male) seeking the first annual renewal of their New Mexico Medical Cannabis Program (NMMCP) license. Seventy-six percent of the patients reported using prescription opioids prior to enrollment in the NMMCP, however, the PMP records showed that only 49% of the patients were actually prescribed opioids in the six months prior to enrollment. Of the 64 patients with verifiable opioid prescriptions prior to NMMCP enrollment, 35 (55%) patients reported having eliminated the use of prescription opioids by the time of license renewal. PMP records showed that 26 patients (63% of patients claiming to have eliminated the use of opioid prescriptions and 41% of all patients with verifiable preenrollment opioid use) showed no prescription opioid activity at their first annual NMMCP renewal visit.
决定批准患者继续参加州政府批准的医用大麻项目具有一定难度，部分原因在于患者症状报告和健康状况报告的准确性存在不确定性，包括对其他药物使用可能产生的任何影响。我们进行了一项实用的便利性研究，比较了131名寻求新墨西哥医用大麻项目（NMMCP）许可证首次年度续签的慢性疼痛患者（平均年龄 = 54岁；54%为男性）在处方监测项目（PMP）中之前和当前处方阿片类药物使用情况的患者报告与阿片类药物处方记录。76%的患者报告在加入NMMCP之前使用过处方阿片类药物，然而，PMP记录显示，在加入前的六个月中，只有49%的患者实际被开具了阿片类药物。在NMMCP注册前有可核实的阿片类药物处方的64名患者中，35名（55%）患者报告在许可证续签时已停止使用处方阿片类药物。PMP记录显示，26名患者（声称已停止使用阿片类药物处方的患者中的63%以及所有有可核实的注册前阿片类药物使用情况的患者中的41%）在其首次NMMCP年度续签就诊时没有处方阿片类药物活动。
